Core Insights - The 25th China Private Equity Annual Conference will be held in Shenzhen from December 2-5, 2025, organized by Qingke Holdings and Investment界 [2] - The event features various forums and summits, including the Investment Trend Forum, AI Summit, and Innovation Drug and Life Science Summit, aimed at enhancing the investment ecosystem [2][10] Agenda Highlights - The Investment Trend Forum will include a 90-minute dialogue focusing on future challenges and opportunities, alongside the release of the "2025 China Private Equity Development Report" [4][6] - Keynote speeches will be delivered by prominent figures such as Ni Zhengdong, founder of Qingke Group, and Jin Haitao, chairman of Qianhai Ark Asset Management [6][7] - Roundtable discussions will cover topics like cyclical strategies, international perspectives, and exit strategies, featuring industry leaders from various investment firms [8][10] AI Summit Focus - The AI Summit will address breakthroughs in the industry, exploring the integration of AI with hard technology and investment logic behind technological advancements [10][12] - Discussions will include the opportunities presented by embodied intelligence and AI applications in real-world scenarios [10][12] Innovation Drug and Life Science Summit - The summit will focus on key advancements in biotechnology, including AI in drug development, cell and gene therapy, and innovations in medical devices [20][21] - Notable speakers include He Fuchu, an academician from the Chinese Academy of Sciences, discussing international scientific initiatives [20][21] Networking Opportunities - The event will feature diverse networking activities, allowing participants to engage with industry leaders and explore innovative technologies [22][24] - Over 20 cutting-edge technology companies will showcase their products, enhancing interaction between investors and startups [24][25]

Core Insights - The 25th China Private Equity Annual Conference will be held in Shenzhen from December 2-5, 2025, organized by Qianhai Capital and Investment界, with various forums and summits focusing on investment trends, AI, and life sciences [2][4]. Agenda Highlights - The conference will feature a 90-minute impactful dialogue at the Investment Trend Forum on December 3, discussing the future of investment with the release of the "2025 China Private Equity Development Report" [4][6]. - Keynote speeches will include prominent figures such as Ni Zhengdong, founder and chairman of Qianhai Group, and Jin Haitao, chairman of Qianhai Ark Asset Management [6][7]. - Roundtable discussions will cover topics like cyclical games, the rise of corporate venture capital (CVC), and hard technology investments, featuring industry leaders from various investment firms [8][18]. AI Summit - The AI Summit on December 3 will focus on breakthroughs in the industry, discussing the "computing power revolution" and the integration of AI with hard technology, providing a platform for investment institutions and enterprises [10][12]. Innovation in Life Sciences - The Innovation Drug and Life Science Summit on December 4 will address key advancements in biotechnology, including AI in drug development and innovative medical devices, offering insights for investors [20][21]. Exhibition and Networking - The conference will feature over 20 innovative technology companies, providing opportunities for networking and engagement through various interactive formats, including discussions with industry leaders and technology showcases [22][24].

Core Viewpoint - Qingke Holdings (01945) announced the establishment of a partnership aimed at early-stage, small-scale, and technology-driven investments, focusing on supporting university student entrepreneurship projects and investing in key areas of Hunan Province's "4×4" modern industrial system [1] Group 1 - The partnership includes Qingke Chuangying, Qingke Chuangye, Hunan Caixin, and Hunan Equity Exchange [1] - The investment focus will be on core sectors such as new generation information technology, advanced manufacturing, biomedicine, and cultural creativity [1] - The establishment of the partnership aligns with the company's long-term strategic considerations to connect with cutting-edge academic innovation resources and explore future technological trends [1] Group 2 - The initiative aims to seek new growth points for the company's sustainable development [1] - It also represents a practical action for the company to fulfill its social responsibility and support the cultivation of innovative talents [1]

Core Viewpoint - Qingke Holdings (01945) has announced the establishment of a partnership aimed at early-stage, small-scale, and technology-driven investments, focusing on supporting university student entrepreneurship projects and investing in key areas of Hunan Province's "4×4" modern industrial system [1] Group 1 - The partnership includes Qingke Chuangying, Qingke Chuangye, Hunan Caixin, and Hunan Equity Exchange [1] - The investment focus will be on new generation information technology, advanced manufacturing, biomedicine, and cultural and creative industries [1] - The establishment of the partnership aligns with the company's long-term development strategy to connect with academic innovation resources and explore future technology trends [1] Group 2 - The initiative aims to seek new growth points for the company's continuous development [1] - It also represents a practical action for the company to fulfill its social responsibility and support the cultivation of innovative talents [1]

Core Viewpoint - Qingke Holdings (01945.HK) announced the establishment of a partnership aimed at early-stage, small-scale, and technology-driven investments, focusing on supporting university student entrepreneurship and investing in key areas of Hunan Province's "4x4" modern industrial system [1] Group 1: Partnership Formation - Qingke Holdings entered into a partnership agreement with Qingke Chuangying, Qingke Chuangye, Hunan Caixin, and Hunan Equity Exchange [1] - The partnership will focus on early-stage investments in technology-driven projects, particularly those initiated by university students [1] Group 2: Investment Focus - The partnership aims to invest in high-growth areas within Hunan Province's "4x4" modern industrial system, including new generation information technology, advanced manufacturing, biomedicine, and cultural creativity industries [1] - The objective is to nurture early-stage technological innovation and support strategic emerging industries [1] Group 3: Strategic Intent - The establishment of the partnership aligns with the company's long-term development strategy, seeking to connect with cutting-edge academic innovation resources and explore future technological trends [1] - This initiative also reflects the company's commitment to social responsibility and the cultivation of innovative talent [1]

ZERO2IPO HOLDINGS INC. 清科控股有限公司* （於 開曼群島註冊成立之有限公司） （股份代號：1945） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 關連交易 成立合夥企業 成立合夥企業 董 事 會 欣 然 宣 佈，於2025年11月26日，清 科 創 盈、清 科 創 業、湖 南 財 信 及 湖 南 股 權 交 易 所 訂 立 合 夥 協 議，據 此，清 科 創 盈、清 科 創 業、湖 南 財信及湖南股權交易所同意共同成立合夥企業。合夥企業旨在聚焦早期、 小 規 模 及 技 術 驅 動 型 投 資，重 點 扶 持 大 學 生 創 業 項 目，並 主 要 投 資 湖 南省「4×4」現代產業體系的核心領域，如新一代信息技術、先進製造業、 生物醫藥及文化創意產業。 本公司的合併聯屬實體之一清科創業將與獨立第三方湖南財信及湖 南股權交易所共同作為合夥企業的有限合 夥 ...

Core Insights - The 25th China Private Equity Annual Conference will be held in Shenzhen from February 2-5, 2025, focusing on innovation in pharmaceuticals and life sciences [2] - The "Innovation Drugs and Life Science Summit" will discuss key advancements in biotechnology, including AI-driven drug development, cell and gene therapy, and medical device innovation [3] Group 1: Event Details - The conference is organized by Qingke Holdings, Investment界, and co-hosted by Huaitong Financial Holdings and Nanshan Zhanxin Investment [2] - A special summit on innovative drugs and life sciences will take place on December 4, featuring discussions on industry trends and investment opportunities [2][3] Group 2: Discussion Topics - Key topics include AI-driven models for next-generation drug development, the new era of innovative medical devices, and collaboration between CXOs and VCs to create a new ecosystem for innovative drugs [5] - Roundtable discussions will feature prominent figures from various sectors, including academia, industry, and investment, providing deep insights into the future of medical investments [7]

Core Viewpoint - The 25th China Private Equity Annual Conference will be held in Shenzhen from February 2-5, 2025, focusing on the intersection of AI and hard technology, exploring investment opportunities and challenges in these fields [2]. Agenda Summary - The AI Summit will cover topics from foundational "computing power revolution" to application-level "industry empowerment," focusing on breakthroughs in embodied intelligence and the practical implementation of AI in the physical world [2]. - The agenda includes keynote speeches and roundtable discussions featuring prominent figures from various tech and investment firms, addressing themes such as AI's integration with hardware and investment strategies for 2025 [4][5]. Notable Speakers - Key speakers include founders and CEOs from companies like SmartMore, Self-Variable Robotics, Yuanrong Qixing, and Boson Quantum, who will engage in deep discussions on the conference topics [5].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2025年10月31日 | | --- | | 狀態: 新提交 | 致：香港交易及結算所有限公司 公司名稱: 清科控股有限公司* 呈交日期: 2025年11月5日 本月底法定/註冊股本總額： USD 50,000 備註： * 僅供識別 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01945 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 299,026,000 | | 6,044,800 | | 305,070,800 | | 增加 / 減少 (-) | | | -1,600 | | 1,600 | | | ...

Core Insights - Malaysia's independent inspection agency Amspec reported that the palm oil export volume for October 1-31 reached 1,501,945 tons, representing a 4.31% increase compared to the same period last month [1] Industry Summary - The palm oil export volume for October shows a positive growth trend, indicating a potential increase in demand or production efficiency within the industry [1] - The reported export figure of 1,501,945 tons highlights the significant scale of Malaysia's palm oil industry and its role in the global market [1]